Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 7/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25854489 | 0.93 | REN (0.44) | JAK2RENHDAC8PSMB5MAPT | |
| SCHEMBL24797599 | 0.89 | REN (0.46) | JAK2RENHDAC8BACE1 | |
| SCHEMBL25854493 | 0.89 | REN (0.46) | JAK2RENHDAC8BACE1 | |
| SCHEMBL17531777 | 0.85 | MEN1 (0.44) | RENHDAC8 | |
| SCHEMBL25854491 | 0.84 | HTR2A (0.44) | JAK2RENHDAC8PSMB5MAPT | |
| SCHEMBL31045408 | 0.83 | KLK5 (0.40) | JAK2RENHDAC8KDM4ENPSR1 | |
| SCHEMBL31045317 | 0.81 | HDAC8 (0.52) | RENHDAC8PPARGPPARA | |
| SCHEMBL25854495 | 0.81 | REN (0.45) | RENPPARGPPARA | |
| SCHEMBL19375787 | 0.81 | LTA4H (0.44) | RENHDAC8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22311901 | 0.79 | PSMB5 (0.56) | RENPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | JAK2 268/4885REN 3338/4885HDAC8 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.